“Screening for prostate cancer has been a public health disaster,” announced Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City. At the center of the debate is the question of whether the benefits of prostate-specific antigen (PSA) screening (namely the reduction in mortality) outweigh the harms (overdiagnosis and overtreatment). According to Dr. Vickers and his colleague Peter R. Carroll, MD, MPH, Professor and Chair, Department of Urology, University of California, San Francisco, the answer depends on screening younger men than in the past, adherence to strict criteria for biopsy, aggressive treatment of men with high-risk disease, and active surveillance for men with low-risk disease. Both Drs. Carroll and Vickers are members of the NCCN Guidelines Panel for Prostate Cancer Early Detection.
AndrioleGLCrawfordEDGrubbRL3rd. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med2009;360:1310–1319.
MoyerVA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2012;157:120–134.
HugossonJCarlssonSAusG. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol2010;11:725–732.
CarrollPRWhitsonJMCooperbergMR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?J Clin Oncol2011;29:345–347.
VickersAJSjobergDDUlmertD. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med2014;12:26.